Sessions Not to Miss at CHEST 2016

October 11, 2016 by Vanessa Claude

Do you know what sessions you’ll be attending at CHEST? There will be a large variety of sessions by curriculum available, but we have some great ones you’ll want to attend on asthma, nontuberculous mycobacteria diseases (NTM), and COPD, focusing on current issues impacting the field. Here is what you should check out:

Asthma

Revisiting Asthma In the Elderly: Current Understanding and Future Needs

Monday, October 24, 7:30-8:30 am
Discuss what we have learned about asthmas pathophysiologic mechanisms, phenotypes, and diagnostic and management challenges and opportunities.

Supported in part by a medical educational program from Teva Pharmaceuticals, an education grant from Meda Pharmaceuticals, and an educational grant from GlaxoSmithKline

A Fresh Look at Severe Asthma

Tuesday, October 25, 2:45-4:15 pm
Update your knowledge in the fields of severe asthma, pathophysiology, phenotypes, biomarkers, and targets of therapy.

Supported in part by an educational grant from GlaxoSmithKline, an education grant from Meda Pharmaceuticals, and a medical educational program from Teva Pharmaceuticals.

All Wheezes Are Definitely Not Asthma: A Focus on Mimickers of Severe Asthma

Wednesday, October 26, 8:45-10:00 am
Identify conditions that may mimic asthma, and recognize atypical signs, symptoms, and radiographic and laboratory findings that suggest conditions with an alternate diagnosis when evaluating a patient with severe asthma.

Supported in part by a medical educational program from Teva Pharmaceuticals, an education grant from Meda Pharmaceuticals, and an educational grant from GlaxoSmithKline

Difficult-to-Treat Asthma: What Are We Missing?

Wednesday, October 26, 11:00 am-12:15 pm
Identify strategies to avoid misdiagnosis of difficult-to-treat asthma by recognizing asthma mimics, and discuss steps to evaluate patients for comorbidities and triggers that can worsen asthma control.

Supported in part by a medical educational program from Teva Pharmaceuticals, an education grant from Meda Pharmaceuticals, and an educational grant from GlaxoSmithKline

What Can We Learn From Allergists About Indoor Air?

Wednesday, October 25, 4:30-5:30 pm
This session will invite allergists to discuss the health effects of bioaerosols, including how to detect them, and strategies to minimize exposure to bioaerosols.

Supported in part by a medical educational program from Teva Pharmaceuticals, an education grant from Meda Pharmaceuticals, and an educational grant from GlaxoSmithKline

NTM (Nontuberculous Mycobacteria Diseases)

Nontuberculous Mycobacteria Lung Infections: Answers to Patients’ FAQs

Sunday, October 23, 3:15-4:15 pm
This session will provide answers, based on the literature, to three frequently asked questions that patients pose to their pulmonary physicians.

Supported by a continuing medical education grant from Insmed Incorporated

Nontuberculous Mycobacteria: Interactive Panel Discussion of Complex Cases

Tuesday, October 25, 11:00 am-12:15 pm
Increase your awareness of NTM and discuss the latest in epidemiology, diagnosis, management, and treatment of NTM in interactive case-based panel discussion.

Supported by a continuing medical education grant from Insmed Incorporated.

Nontuberculous Lung Infections for the Community-Based Pulmonologist: Who to Treat, Who to Refer

Wednesday, October 26, 11:00 am-12:15 pm
Use a case-based format to review the evaluation and treatment of patients with nontuberculous mycobacterial infections.

Supported by a continuing medical education grant from Insmed Incorporated

COPD

Clinical Applications for Measuring Lung Volumes in COPD

Sunday, October 23, 7:30-8:30 am
Describe the clinical importance of improvement in FVC with bronchodilation in COPD, and review the contribution of hyperinflation (FRC) and air trapping (RV) to impairment and dyspnea in COPD.

Supported in part by an independent medical education grant from Mylan Specialty L.P., an educational grant from GlaxoSmithKline, and an independent educational grant from AstraZeneca LP.

COPD Phenotypes: What Do We Know So Far?

Sunday, October 23, 10:45 am-12:00 pm
Focus on identifying current COPD phenotypes and their clinical, physiologic, and radiologic characteristics and understanding the multifactorial aspect of COPD and its relationship with multiple comorbidities.

Supported in part by an independent medical education grant from Mylan Specialty L.P., an educational grant from GlaxoSmithKline, and an independent educational grant from AstraZeneca LP.

COPD and Home-Based NIV: Clinical Controversy

Sunday, October 23, 4:30-5:30 pm
Identify differences between COPD/OSA overlap syndrome and compare and contrast factors that help differentiate high-intensity and low-intensity pressure support therapy.

Supported in part by an independent medical education grant from Mylan Specialty L.P., an educational grant from GlaxoSmithKline, and an independent educational grant from AstraZeneca LP.

Uncertainties in Pharmacotherapy for COPD

Monday, October 24, 11:00 am-12:00 pm
Consider the role of dual (LAMA/LABA) bronchodilators in the treatment paradigm of patients with COPD, and review the current use of inhaled corticosteroids in the treatment of COPD and describe recommended indications.

Supported in part by an independent medical education grant from Mylan Specialty L.P., an educational grant from GlaxoSmithKline, and an independent educational grant from AstraZeneca LP.

Absence Makes the Heart Grow Fonder: Preventing COPD Readmissions

Monday, October 24, 3:15-4:15 pm
Learn treatment options that will prevent exacerbations. Use of CHEST evidence-based guidelines to direct management will be highlighted.

Supported in part by an independent medical education grant from Mylan Specialty L.P., an educational grant from GlaxoSmithKline, and an independent educational grant from AstraZeneca LP.

Should Bronchodilator Responsiveness Be Assessed in All COPD Patients?

Monday, October 24, 3:15-4:15 pm
Review ideal pre- and postbronchodilator testing procedures as recommended, and describe criteria for determining what is reversibility.

Supported in part by an independent medical education grant from Mylan Specialty L.P., an educational grant from GlaxoSmithKline, and an independent educational grant from AstraZeneca LP.

COPD 2017

Tuesday, October 25, 2:45-4:15 pm
This session will provide an update on our understanding of COPD.

Supported in part by an independent education grant from AstraZeneca LP, an educational grant from GlaxoSmithKline, and an independent medical educational grant from Mylan Specialty L.P.

The INSPIRED COPD Outreach Program: Taking a Successful Innovation to New Levels

Wednesday, October 26, 11:00 am-12:15 pm
Learn new strategies to manage the care of patients and families living with advanced COPD and the associated heavy symptom burden.

Supported in part by an independent medical education grant from Mylan Specialty L.P., an educational grant from GlaxoSmithKline, and an independent educational grant from AstraZeneca LP.

Make sure to add these sessions to your schedule. You won’t want to miss them! Find further details about these sessions on our CHEST Events app. The CHEST Events app is available for download on iPhone and Android or access the mobile website.


  • Sign up below to receive an email when new blog posts are available.